# Compare Tesamorelin and Retatrutide — Vyra Peptides

> A side-by-side comparison of tesamorelin and retatrutide across peptide class, most-studied population, evidence base, administration studied, regulatory status, and key caution.

Where tesamorelin and retatrutide converge on the visceral-fat question, where they diverge in mechanism and approval status, and what the effect sizes actually look like at the population level.

## The short version

This page lines up [tesamorelin](/tesamorelin) and [retatrutide](/retatrutide) on the dimensions that matter most when reading metabolic research peptides: peptide class, which populations were studied, strength of evidence, administration route, regulatory standing, and the single biggest caveat for each. The headline is crisp. Tesamorelin is FDA-approved — but only for one narrowly defined condition (HIV-associated lipodystrophy) — and has the most precisely quantified visceral-fat data in the published literature. Retatrutide is investigational with no approved indication as of mid-2026, but its Phase 2 weight-loss signal of ~24% body-weight reduction at 48 weeks is the largest published in the incretin class. Neither is an approved general-use weight-loss therapy, and neither is presented here with a human dose.

## The comparison matrix

| Dimension | Tesamorelin | Retatrutide |
| --- | --- | --- |
| Peptide class | Synthetic GHRH analogue (44 aa); DPP-IV-resistant via N-terminal trans-3-hexenoyl modification | Investigational triple incretin receptor agonist (39 aa); C20 fatty-diacid acylated for albumin binding, once-weekly dosing |
| Most-studied in | HIV-infected adults with antiretroviral-related lipodystrophy | Adults with obesity (BMI ≥30), type 2 diabetes, MASLD |
| Evidence base (model) | Multiple RCTs; 2026 meta-analysis (5 RCTs); FDA-approved [1][3][6] | Phase 2 only (no Phase 3 results yet); three Phase 2 trials published [10][11][12] |
| Administration studied | Subcutaneous injection, once daily (2 mg/day in pivotal trials) [3][6] | Subcutaneous injection, once weekly (up to 12 mg in Phase 2) [11] |
| Regulatory status | FDA-approved (NDA 022505, 2010) for HIV lipodystrophy only; off-label use is investigational; WADA S2 prohibited [2][7] | Investigational (Eli Lilly TRIUMPH Phase 3 program); not approved by any regulator as of mid-2026; WADA classification not yet determined [8] |
| Key caution | Indication-locked: all non-HIV use is off-label; VAT reaccumulates on discontinuation; IGF-1 elevation; WADA prohibited [2][5] | Investigational status: no approved supply, gray-market purity unverified; dose-dependent GI AEs and heart-rate increase; long-term outcomes unknown [11] |

## Peptide class

The two compounds are mechanistically unrelated. Tesamorelin is a GHRH analogue — it works upstream of GH, triggering the pituitary to release GH in its natural pulsatile rhythm, which then drives visceral lipolysis via the GH/IGF-1 axis. Retatrutide operates entirely within the incretin system: it is a three-receptor agonist whose GLP-1, GIP, and glucagon arms work directly on gut-hormone signaling, adipose tissue, and energy expenditure. The two represent different generations of metabolic pharmacology — one derived from the growth-hormone axis, one from incretin biology [4][9].

## Most-studied population

This distinction is clinically important. Every well-powered tesamorelin trial was conducted in HIV-positive adults on antiretroviral therapy who had developed lipodystrophy — a specific, drug-induced redistribution of body fat. The 2026 meta-analysis pooled five such RCTs [1]. Generalizing those effect sizes to non-HIV populations is mechanistically plausible but unvalidated by large trials [2]. Retatrutide's Phase 2 programs enrolled broader populations: adults with obesity (regardless of HIV status), adults with type 2 diabetes, and adults with MASLD [10][11][12]. Neither compound has completed Phase 3 trials in general populations for general weight loss.

## Evidence base

Tesamorelin has the more mature evidence base — a 2026 meta-analysis quantifying effects across five RCTs, plus the pivotal Phase 3 trial and 52-week extension data that underpinned FDA approval [1][5][6]. Effect sizes are well-characterized: mean VAT reduction 27.71 cm2, trunk fat -1.18 kg, hepatic fat fraction -4.28%, lean mass +1.42 kg [1]. Retatrutide's evidence is more recent and still in Phase 2: the obesity trial (n=338, 48 weeks, -24.2% body weight at 12 mg [11]), the T2D trial (n=281, 36 weeks, HbA1c -2.02% [12]), and the MASLD substudy (n=98, liver fat -82.4% at 24 weeks [10]). Phase 3 data from the TRIUMPH program are pending; long-term outcomes trials are ongoing.

## Administration studied

Both compounds are administered by subcutaneous injection, but on different schedules. Tesamorelin was studied at 2 mg/day (once daily) in all pivotal trials [3][6]. Retatrutide uses once-weekly subcutaneous injection at doses up to 12 mg in Phase 2, enabled by the albumin-binding fatty-acid acylation that extends half-life [11]. Daily versus weekly injection is a practical distinction; neither route has been studied in non-research settings outside clinical trials.

## Regulatory and WADA status

Tesamorelin is FDA-approved as a prescription drug — but that approval is bounded to HIV-associated lipodystrophy. All use outside that indication is off-label and investigational. It is explicitly prohibited in sport by the WADA Prohibited List under S2 (peptide hormones, growth factors, related substances and mimetics) in- and out-of-competition [7]. Retatrutide is investigational — not approved by any regulatory agency as of mid-2026, not available as a prescription drug, and only available outside clinical trials through unregulated research-grade channels whose identity and purity cannot be verified. WADA classification for GIP/GLP-1/glucagon receptor agonists is evolving and should be confirmed from the current Prohibited List [8].

## Key caution

For tesamorelin, the defining caution is indication-lock and reaccumulation: its benefits are real but narrow (HIV lipodystrophy), require continuous dosing to maintain (visceral fat re-accumulates on stopping [5]), and come with an IGF-1 elevation that creates a labeled contraindication for active malignancy [2]. For retatrutide, the defining caution is investigational uncertainty: no approved supply means gray-market material lacks verified identity, purity, or sterility; GI adverse events and heart-rate elevation are dose-dependent and were the drivers of discontinuation in Phase 2; and all pivotal outcomes trials are still running, leaving cardiovascular, renal, and long-term weight-regain data open [11].

---

A data-forward literature digest — effect sizes and citations, not recommendations, and nothing for sale.